DND PharmaTech

DND PharmaTech FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of DND PharmaTech (347850.KQ) as of Nov 4, 2026 is 90.02 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 77.63 % — a change of 15.95% (higher).

FCF Conversion

90.02 %

YoY

15.95%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of DND PharmaTech is 2025 90.02 % . FCF Conversion Rate (FCF/EBITDA) of DND PharmaTech was 2024 77.63 % . It decreases by 15.95% higher compared to the previous year.

The DND PharmaTech FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2021
79.39 KRW
Jan 1, 2022
39.54 KRW
Jan 1, 2023
-232.92 KRW
Jan 1, 2024
77.63 KRW
Jan 1, 2025
90.02 KRW
The DND PharmaTech FCF Conversion history
YEARFCF ConversionYoY
90.02 %+15.95%
77.63 %-133.33%
-232.92 %-689.06%
39.54 %-50.19%
79.39 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DND PharmaTech Stock analysis

What does DND PharmaTech do? DND PharmaTech Inc generates revenue primarily through its research and development activities focused on metabolic disease, neurodegenerative, and fibrotic diseases. The company develops therapeutic medicines for diabetes, obesity, and nonalcoholic steatohepatitis as part of its product pipeline. Clinical-stage biotech companies like DND PharmaTech typically secure funding through partnerships, grants, and potential future licensing agreements with pharmaceutical firms. The target segments include pharmaceutical companies seeking innovative drug candidates and healthcare providers interested in new treatment options for complex conditions. The company's product pipeline targets indications such as metabolic disease, neurodegenerative, and fibrotic diseases. Its research focuses on therapeutic medicines for diabetes, obesity, and nonalcoholic steatohepatitis. DND PharmaTech operates as a clinical-stage biotech firm, meaning it is developing drugs but has not yet commercialized them. The primary buyers of its R&D services and potential future products would be pharmaceutical companies looking to expand their portfolios with new therapies. DND PharmaTech Inc's business model centers on developing innovative treatments for high-need medical conditions. The firm's focus on metabolic disease, neurodegenerative, and fibrotic diseases positions it to address significant unmet medical needs. Its pipeline includes therapeutic medicines for diabetes, obesity, and nonalcoholic steatohepatitis, which are areas with growing market demand. The company's clinical-stage status indicates it is still in the development phase rather than commercial production. DND PharmaTech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DND PharmaTech stock

FCF Conversion Rate (FCF/EBITDA) of DND PharmaTech is 90.02 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of DND PharmaTech changed from 77.63 % to 90.02 %, representing a 15.95% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) DND PharmaTech since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s DND PharmaTech with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — DND PharmaTech

All Key Metrics — DND PharmaTech